<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124540">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02101073</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0061-C102</org_study_id>
    <secondary_id>2013-005493-21</secondary_id>
    <nct_id>NCT02101073</nct_id>
  </id_info>
  <brief_title>ALX-0061 Phase I Bioavailability Study in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aims of the study are:

        -  To assess the bioavailability of single doses of ALX-0061, administered s.c. at three
           dose levels, using 2 corresponding single i.v. dose levels as reference.

        -  To provide additional information on pharmacokinetics and pharmacodynamics of ALX-0061.

        -  To further determine the safety and tolerability of ALX-0061.

        -  To further evaluate the systemic (serum) immunogenicity of ALX-0061.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: serum concentration of ALX-0061 after single subcutaneous (s.c.) and single intravenous (i.v.) doses of ALX-0061 in healthy volunteers</measure>
    <time_frame>Day 1 to Day 32 +/- 2 days after dosing for low dose treatment arms, Day 1 to Day 46 +/-2 days after dosing for middle dose treatment arm, Day 1 to Day 53 +/- 2 days after dosing for high dose treatment arms</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: concentration in plasma of total soluble Interleukin-6 receptor (sIL-6R) and in serum of IL-6</measure>
    <time_frame>During screening untill final visit (i.e. 60 +/- 2 days after dosing for the low dose and middle dose treatment arms and 83 +/- 2 days after dosing for the high dose treatment arms)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: safety markers</measure>
    <time_frame>From signing of informed consent until final visit (i.e. 60 +/- 2 days for the low dose and middle dose treatment arms and 83 +/- 2 days for the high dose treatment arms</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events and concomitant medication
Clinical laboratory
Vital signs
12-lead ECG
Physical examination
Local reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: concentration of Anti-Drug Antibodies (ADA) in serum</measure>
    <time_frame>From screening until final visit (i.e. 60+/- 2 days after dosing for the low dose and middle dose treatment arms and 83 +/- 2 days after dosing for the high dose treatment arms</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ALX-0061 low dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 high dose i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 low dose s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 middle dose s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALX-0061 high dose s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0061</intervention_name>
    <description>single dose, intravenous</description>
    <arm_group_label>ALX-0061 low dose i.v.</arm_group_label>
    <arm_group_label>ALX-0061 high dose i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0061</intervention_name>
    <description>single dose, subcutaneous</description>
    <arm_group_label>ALX-0061 low dose s.c.</arm_group_label>
    <arm_group_label>ALX-0061 middle dose s.c.</arm_group_label>
    <arm_group_label>ALX-0061 high dose s.c.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Healthy volunteers.

          2. Gender: male or female.

          3. Age 18 to 55 years.

          4. Body mass index (BMI): 18.0 â‰¥ BMI &lt; 30.0 kg/m2.

        Key Exclusion Criteria:

          1. Any active inflammatory condition, or autoimmune disorder such as lupus
             erythematosus, multiple sclerosis or rheumatoid arthritis (RA).

          2. Any current or recent (within 4 weeks prior to dose) signs or symptoms of infection
             that requires parenteral antibiotic administration.

          3. Symptomatic infection, or suspicion thereof in the last 1 week prior to dosing.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven De Bruyn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ablynx NV Belgium</last_name>
    <phone>3292620000</phone>
    <email>clinicaltrials@ablynx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <zip>9470</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
